Selected research
Industry Research
Vaccines for Cancer Industry Research Report 2026
Market perspective
The global Vaccines for Cancer market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Vaccines for Cancer is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Vaccines for Cancer is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Vaccines for Cancer include Ultimovacs, Sellas Life Sciences, OncoPep, Marker Therapeutics, Inc., Immatics, Immatics, Anergis, AmbioPharm and Almac, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Vaccines for Cancer market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vaccines for Cancer Market by Company
Ultimovacs
Sellas Life Sciences
OncoPep
Marker Therapeutics, Inc.
Immatics
Immatics
Anergis
AmbioPharm
Almac
ACT
Vaccines for Cancer Segment by Type
Synthetic Polypeptide Vaccines
Recombinant Polypeptide Vaccine
Other
Vaccines for Cancer Segment by Application
Infectious Disease Prevention
Cancer Immunotherapy
Other
Vaccines for Cancer Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccines for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaccines for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccines for Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Vaccines for Cancer manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Vaccines for Cancer by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Vaccines for Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Synthetic Polypeptide Vaccines
- Recombinant Polypeptide Vaccine
- Other
Applications
- Infectious Disease Prevention
- Cancer Immunotherapy
- Other
Companies covered
- Ultimovacs
- Sellas Life Sciences
- OncoPep
- Marker Therapeutics, Inc.
- Immatics
- Immatics
- Anergis
- AmbioPharm
- Almac
- ACT
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Vaccines for Cancer Market Size (2021-2032)
- 2.2.2 Global Vaccines for Cancer Sales (2021-2032)
- 2.2.3 Global Vaccines for Cancer Market Average Price (2021-2032)
- 2.3 Vaccines for Cancer by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Synthetic Polypeptide Vaccines
- 2.3.3 Recombinant Polypeptide Vaccine
- 2.3.4 Other
- 2.4 Vaccines for Cancer by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Infectious Disease Prevention
- 2.4.3 Cancer Immunotherapy
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Vaccines for Cancer Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Vaccines for Cancer Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Vaccines for Cancer Revenue of Manufacturers (2021-2026)
- 3.4 Global Vaccines for Cancer Average Price by Manufacturers (2021-2026)
- 3.5 Global Vaccines for Cancer Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Vaccines for Cancer, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Vaccines for Cancer, Product Type & Application
- 3.8 Global Manufacturers of Vaccines for Cancer, Established Date
- 3.9 Global Vaccines for Cancer Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Ultimovacs
- 4.1.1 Ultimovacs Company Information
- 4.1.2 Ultimovacs Business Overview
- 4.1.3 Ultimovacs Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Ultimovacs Vaccines for Cancer Product Portfolio
- 4.1.5 Ultimovacs Recent Developments
- 4.2 Sellas Life Sciences
- 4.2.1 Sellas Life Sciences Company Information
- 4.2.2 Sellas Life Sciences Business Overview
- 4.2.3 Sellas Life Sciences Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sellas Life Sciences Vaccines for Cancer Product Portfolio
- 4.2.5 Sellas Life Sciences Recent Developments
- 4.3 OncoPep
- 4.3.1 OncoPep Company Information
- 4.3.2 OncoPep Business Overview
- 4.3.3 OncoPep Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 OncoPep Vaccines for Cancer Product Portfolio
- 4.3.5 OncoPep Recent Developments
- 4.4 Marker Therapeutics, Inc.
- 4.4.1 Marker Therapeutics, Inc. Company Information
- 4.4.2 Marker Therapeutics, Inc. Business Overview
- 4.4.3 Marker Therapeutics, Inc. Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Marker Therapeutics, Inc. Vaccines for Cancer Product Portfolio
- 4.4.5 Marker Therapeutics, Inc. Recent Developments
- 4.5 Immatics
- 4.5.1 Immatics Company Information
- 4.5.2 Immatics Business Overview
- 4.5.3 Immatics Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Immatics Vaccines for Cancer Product Portfolio
- 4.5.5 Immatics Recent Developments
- 4.6 Immatics
- 4.6.1 Immatics Company Information
- 4.6.2 Immatics Business Overview
- 4.6.3 Immatics Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Immatics Vaccines for Cancer Product Portfolio
- 4.6.5 Immatics Recent Developments
- 4.7 Anergis
- 4.7.1 Anergis Company Information
- 4.7.2 Anergis Business Overview
- 4.7.3 Anergis Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Anergis Vaccines for Cancer Product Portfolio
- 4.7.5 Anergis Recent Developments
- 4.8 AmbioPharm
- 4.8.1 AmbioPharm Company Information
- 4.8.2 AmbioPharm Business Overview
- 4.8.3 AmbioPharm Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 AmbioPharm Vaccines for Cancer Product Portfolio
- 4.8.5 AmbioPharm Recent Developments
- 4.9 Almac
- 4.9.1 Almac Company Information
- 4.9.2 Almac Business Overview
- 4.9.3 Almac Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Almac Vaccines for Cancer Product Portfolio
- 4.9.5 Almac Recent Developments
- 4.10 ACT
- 4.10.1 ACT Company Information
- 4.10.2 ACT Business Overview
- 4.10.3 ACT Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 ACT Vaccines for Cancer Product Portfolio
- 4.10.5 ACT Recent Developments
5 Global Vaccines for Cancer Market Scenario by Region
- 5.1 Global Vaccines for Cancer Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Vaccines for Cancer Sales by Region: 2021-2032
- 5.2.1 Global Vaccines for Cancer Sales by Region: 2021-2026
- 5.2.2 Global Vaccines for Cancer Sales by Region: 2027-2032
- 5.3 Global Vaccines for Cancer Revenue by Region: 2021-2032
- 5.3.1 Global Vaccines for Cancer Revenue by Region: 2021-2026
- 5.3.2 Global Vaccines for Cancer Revenue by Region: 2027-2032
- 5.4 North America Vaccines for Cancer Market Facts & Figures by Country
- 5.4.1 North America Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Vaccines for Cancer Sales by Country (2021-2032)
- 5.4.3 North America Vaccines for Cancer Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Vaccines for Cancer Market Facts & Figures by Country
- 5.5.1 Europe Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Vaccines for Cancer Sales by Country (2021-2032)
- 5.5.3 Europe Vaccines for Cancer Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Vaccines for Cancer Market Facts & Figures by Country
- 5.6.1 Asia Pacific Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Vaccines for Cancer Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Vaccines for Cancer Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Vaccines for Cancer Market Facts & Figures by Country
- 5.7.1 South America Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Vaccines for Cancer Sales by Country (2021-2032)
- 5.7.3 South America Vaccines for Cancer Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Vaccines for Cancer Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Vaccines for Cancer Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Vaccines for Cancer Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Vaccines for Cancer Sales by Type (2021-2032)
- 6.1.1 Global Vaccines for Cancer Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Vaccines for Cancer Sales Market Share by Type (2021-2032)
- 6.2 Global Vaccines for Cancer Revenue by Type (2021-2032)
- 6.2.1 Global Vaccines for Cancer Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Vaccines for Cancer Revenue Market Share by Type (2021-2032)
- 6.3 Global Vaccines for Cancer Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Vaccines for Cancer Sales by Application (2021-2032)
- 7.1.1 Global Vaccines for Cancer Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Vaccines for Cancer Sales Market Share by Application (2021-2032)
- 7.2 Global Vaccines for Cancer Revenue by Application (2021-2032)
- 7.2.1 Global Vaccines for Cancer Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Vaccines for Cancer Revenue Market Share by Application (2021-2032)
- 7.3 Global Vaccines for Cancer Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Vaccines for Cancer Value Chain Analysis
- 8.1.1 Vaccines for Cancer Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Vaccines for Cancer Production Mode & Process
- 8.2 Vaccines for Cancer Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Vaccines for Cancer Distributors
- 8.2.3 Vaccines for Cancer Customers
9 Global Vaccines for Cancer Analyzing Market Dynamics
- 9.1 Vaccines for Cancer Industry Trends
- 9.2 Vaccines for Cancer Industry Drivers
- 9.3 Vaccines for Cancer Industry Opportunities and Challenges
- 9.4 Vaccines for Cancer Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst